Pulsed Electromagnetic Field Treatment for Alzheimer's Disease
Trial Summary
Will I have to stop taking my current medications?
If you are taking a cholinesterase inhibitor or memantine, you must have been on a stable dose for at least 60 days before the trial and continue that dose during the study. If you are taking anti-amyloid monoclonal antibodies, you must have stopped at least 3 months before the trial. The protocol does not specify other medication restrictions, but you cannot take medications that lower the seizure threshold.
What data supports the effectiveness of the ECHS AD Device treatment for Alzheimer's Disease?
Research shows that electromagnetic field (EMF) treatments, similar to the ECHS AD Device, have been effective in improving cognitive function in Alzheimer's disease models and are considered safe. Additionally, non-invasive brain stimulation techniques, like transcranial electrical stimulation, have shown promise in treating cognitive impairments associated with Alzheimer's.12345
Is Pulsed Electromagnetic Field Treatment safe for humans?
Research suggests that Pulsed Electromagnetic Field (PEMF) treatment is generally safe for humans, with studies showing no harmful effects on general health or cognitive function. Some studies even report beneficial effects on brain function, and there is no evidence linking PEMF exposure to an increased risk of cancer.56789
How does the ECHS AD Device treatment differ from other Alzheimer's treatments?
The ECHS AD Device uses pulsed electromagnetic fields (PEMF) to treat Alzheimer's, which is unique because it targets the disease by reducing amyloid-beta protein aggregation in the brain, a key factor in Alzheimer's progression. Unlike traditional treatments that only manage symptoms, this non-invasive approach aims to address the underlying disease process and improve cognitive function.510111213
What is the purpose of this trial?
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Eligibility Criteria
This trial is for individuals with mild to moderate Alzheimer's Disease. Participants will use the ECHS AD device at home, three times a day for 15 minutes over a period of 120 days. The study requires follow-up for 9 months post-treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pulsed electromagnetic field treatment at home three times a day for 15 minutes over 120 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ECHS AD Device
Find a Clinic Near You
Who Is Running the Clinical Trial?
Herrick Medical LLC
Lead Sponsor
University of Miami
Collaborator